Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citationHaloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.10.1195 · Cited by 323
Intensive Behavioral/Psychoeducational Treatments for Autism: Research Needs and Future Directions
Schreibman, L. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005535120023 · Cited by 268
The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children
Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02211843 · Cited by 241
Neuroleptic-Related Dyskinesias in Autistic Children: A Prospective, Longitudinal Study
CAMPBELL, M., ARMENTEROS, J. L., MALONE, R. P., ADAMS, P. B., EISENBERG, Z. W., & OVERALL, J. E. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00022 · Cited by 236
Buitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0405 · Cited by 236
MCDOUGLE, C. J., HOLMES, J. P., BRONSON, M. R., ANDERSON, G. M., VOLKMAR, F. R., PRICE, L. H., & COHEN, D. J. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199705000-00020 · Cited by 211
Self-citationResearch Units on Pediatric Psychopharmacology (Rupp) Autism Network
McDougle, C. J., Scahill, L., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., Freeman, B. J., Martin, A., McGough, J. J., Cronin, P., et al. (2000) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/s1056-4993(18)30142-1 · Cited by 179
Self-citationMarshburn, E. C., & Aman, M. G. (1992) · Journal of Autism and Developmental Disorders · doi:10.1007/bf01048240 · Cited by 171
Self-citationBrown, E. C., Aman, M. G., & Havercamp, S. M. (2002) · Research in Developmental Disabilities · doi:10.1016/s0891-4222(01)00091-9 · Cited by 152
Self-citationTreatment with atypical antipsychotics: new indications and new populations
Glick, I. D., Murray, S. R., Vasudevan, P., Marder, S. R., & Hu, R. J. (2001) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(01)00020-6 · Cited by 143
Prevalence of infantile autism in four French regions
Fombonne, E. J., & du Mazaubrun, C. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00789007 · Cited by 133
Arnold, L. E., Aman, M. G., Martin, A., Collier-Crespin, A., Vitiello, B., Tierney, E., Asarnow, R. F., Bell-Bradshaw, F., Freeman, B. J., Gates-Ulanet, P., et al. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005451304303 · Cited by 128
Self-citationUse of Risperidone in Pervasive Developmental Disorders: A Case Series
FISMAN, S., & STEELE, M. (1996) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.1996.6.177 · Cited by 82
Atypical antipsychotics in persons with developmental disabilities
Aman, M. G., & Madrid, A. (1999) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/(sici)1098-2779(1999)5:4<253::aid-mrdd2>3.0.co;2-r · Cited by 57
Self-citationReview of serotonergic agents and perseverative behavior in patients with developmental disabilities
Aman, M. G., Arnold, L. E., & Armstrong, S. C. (1999) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/(sici)1098-2779(1999)5:4<279::aid-mrdd5>3.0.co;2-6 · Cited by 51
Self-citationScahill, L., McCracken, J., McDougle, C. J., Aman, M., Arnold, L. E., Tierney, E., Cronin, P., Davies, M., Ghuman, J., Gonzalez, N., et al. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601317261555 · Cited by 42
Self-citation
Cited by
Lord, C., Brugha, T. S., Charman, T., Cusack, J., Dumas, G., Frazier, T., Jones, E. J. H., Jones, R. M., Pickles, A., State, M. W., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0138-4 · Cited by 1,859
Comorbid psychiatric disorders in children with autism: interview development and rates of disorders
Leyfer, O. T., Folstein, S. E., Bacalman, S., Davis, N. O., Dinh, E., Morgan, J., Tager-Flusberg, H., & Lainhart, J. E. (2006) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-006-0123-0 · Cited by 1,637
“They are the Aberrant Behavior Checklist (Aman, Singh, Stewart, & Field, 1985; McCracken et al., 2002; Rojahn, Aman, Matson, & Mayville, 2003), the Developmental Behavior Checklist (Clarke, Tonge, Einfeld, & Mackinnon, 2003; Dekker, Nunn, Einfeld, Tonge, & Koot, 2002b; Einfeld, Tonge, Turner, Parmenter, & Smith, 1999;…”
Identification, Evaluation, and Management of Children With Autism Spectrum Disorder
Hyman, S. L., Levy, S. E., Myers, S. M., COUNCIL ON CHILDREN WITH DISABILITIES, S. O. D. A. B. P., Kuo, D. Z., Apkon, S., Davidson, L. F., Ellerbeck, K. A., Foster, J. E. A., Noritz, G. H., et al. (2020) · Pediatrics · doi:10.1542/peds.2019-3447 · Cited by 1,798
Evidence-Based Psychosocial Treatments for Children and Adolescents With Disruptive Behavior
Eyberg, S. M., Nelson, M. M., & Boggs, S. R. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701820117 · Cited by 1,335
“…aggression have found the atypical antipsychotic drug risperidone effective for reducing aggressive behaviors in youth with CD (Findling et al., 2000), with below-average IQ (Aman et al., 2002; Buitelaar, van der Gaag, Cohen-Kettenis, & Melman, 2001), and with autism (McCracken et al., 2002).”
BackgroundSecond-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.